Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

A Double-blind, Randomised, 3-way Cross-over Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin ER Extended Release (ER) 200 mg Dipyridamole/25 mg ASA Formulations in Healthy Male and Female Volunteers

Comparative pharmacokinetics of dipyridamole in two new formulations of Asasantin ER compared to the present commercial formulation

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Asasantin ER, present commercial formulation; Drug: Asasantin ER, new formulation I; Drug: Asasantin ER, new formulation II

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• All participants in the study should be healthy males or females, range from 21 to 50 years of age and be within ± 20 % of their normal weight (Broca-Index)
• Prior to admission to the study all volunteers will have given, in accordance with good clinical practice (GCP) and the local legislation, their written informed consent
• Subsequently each subject will have his medical history taken and will receive a complete medical examination (incl. blood pressure and pulse rate measurements) as well as a 12-lead ECG
• Hematopoietic, hepatic and renal function tests will be carried out in the laboratory
• The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations
• The above mentioned examinations will be performed within 14 days before the first administration of the test substance

Exclusion Criteria:

• Volunteers are excluded from the study if the results of the medical examination or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
• Subjects with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Subjects with diseases of the central nervous system (such as epilepsy) or with psychiatric or neurological disorders
• History of orthostatic hypotension, fainting spells or blackouts
• Subjects with chronic or relevant acute infections
• Subjects with allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• Volunteers who have taken a drug with a long half-life (≥ 24 hours) within one month or less than ten half-lives of the respective drug before enrolment in the study
• Volunteers who receive any other drugs which might influence the results of the trial during the week previous to enrolment in the study
• Volunteers who participate in another study with an investigational drug within the last two months preceding the study
• Volunteers who are unable to refrain from smoking on study days
• Volunteers who smoke more than10 cigarettes (or equivalent) per day
• Volunteers who drink more than 60 g of alcohol per day
• Volunteers who are dependent on drugs
• Volunteers who donate blood (≥ 100 mL) within the last four weeks
• Volunteers who participate in excessive physical activities within the last week before the study (e.g. competitive sports)
• Volunteers who suffer from any other disease or abnormality of clinical relevance
• History of hemorrhagic diatheses
• History of gastro-intestinal ulcer, perforation or bleeding
• History of bronchial asthma
• History of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency

Female subjects:

• Pregnancy
• Positive pregnancy test
• No adequate contraception (adequate contraception e.g. sterilization, intrauterine devices (IUD), oral contraceptives)
• Inability to maintain this adequate contraception during the whole study period
• Lactation period

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Asasantin ER, present commercial formulation	Drug: Asasantin ER, present commercial formulation
Experimental: Asasantin ER, new formulation I	Drug: Asasantin ER, new formulation I
Experimental: Asasantin ER, new formulation II	Drug: Asasantin ER, new formulation II

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under the concentration-time curve of dipyridamole in plasma at steady state (AUC,ss)	Up to 48 hours after start of drug administration
Percent peak trough fluctuation of dipyridamole in plasma (%PTF)	Up to 48 hours after start of drug administration

Secondary Outcome Measures

Outcome Measure	Time Frame
Maximum concentration of the analytes in plasma at steady state (Cmax,ss)	Up to 48 hours after start of drug administration
Minimum measured concentration of the analytes in plasma at steady state over a uniform dosing interval τ (Cmin,ss)	Up to 48 hours after start of drug administration
Time from dosing to the maximum measured concentration of the analytes in plasma at steady state over a uniform dosing interval τ Time from dosing to the maximum measured concentration of the analytes in plasma at steady state (tmax,ss)	Up to 48 hours after start of drug administration
Percent area under the curve fluctuation of the analytes in plasma (AUCfluct)	Up to 48 hours after start of drug administration
Terminal half-life of the analytes in plasma (t1/2)	Up to 48 hours after start of drug administration
Percent of dose of the analytes recovered unchanged in urine (Ae%)	Up to 24 hours after start of drug administration
Ratio of peak concentration of the analytes in plasma over area under the curve at steady state (Cmax,ss / AUC,ss)	Up to 48 hours after start of drug administration
Number of subjects with clinically relevant changes in vital signs (blood pressure, pulse rate)	up to 8 days after last study drug administration
Number of subjects with clinically relevant changes in 12-lead ECG	up to 8 days after last study drug administration
Number of subjects with clinically relevant changes in laboratory values	up to 8 days after last study drug administration
Number of subjects with adverse events	up to 8 days after last study drug administration

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start: April 1, 2001
• Primary Completion (Actual): May 1, 2001

Study Registration Dates

• First Submitted: October 23, 2014
• First Submitted That Met QC Criteria: October 23, 2014
• First Posted (Estimate): October 24, 2014

Study Record Updates

• Last Update Posted (Estimate): October 24, 2014
• Last Update Submitted That Met QC Criteria: October 23, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Platelet Aggregation Inhibitors; Aspirin, Dipyridamole Drug Combination
• Other Study ID Numbers: 9.144